News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
801,442 Results
Type
Article (73505)
Company Profile (693)
Press Release (727244)
Section
Business (227058)
Career Advice (3695)
Deals (39232)
Drug Delivery (115)
Drug Development (89014)
Employer Resources (194)
FDA (17728)
Job Trends (17073)
News (386898)
Policy (38644)
Tag
Academia (2974)
Alliances (55577)
Alzheimer's disease (1327)
Approvals (17626)
Artificial intelligence (149)
Bankruptcy (392)
Best Places to Work (12492)
Biotechnology (474)
Breast cancer (125)
Cancer (1083)
Career advice (3145)
Cell therapy (245)
Clinical research (70153)
Collaboration (376)
Compensation (190)
COVID-19 (2796)
C-suite (96)
Data (1006)
Diabetes (161)
Diagnostics (6657)
Drug pricing (101)
Earnings (91705)
Employer resources (167)
Events (125372)
Executive appointments (282)
FDA (18227)
Funding (330)
Gene therapy (181)
GLP-1 (686)
Government (4993)
Healthcare (20692)
Infectious disease (2885)
Inflammatory bowel disease (118)
Interviews (721)
IPO (17503)
Job creations (4982)
Job search strategy (2585)
Layoffs (485)
Legal (9842)
Lung cancer (177)
Manufacturing (184)
Medical device (14385)
Medtech (14390)
Mergers & acquisitions (21747)
Metabolic disorders (449)
Neuroscience (1608)
NextGen Class of 2024 (7615)
Non-profit (5061)
Northern California (1375)
Obesity (261)
Opinion (242)
Patents (105)
People (62873)
Pharmaceutical (137)
Phase I (21623)
Phase II (30599)
Phase III (23095)
Pipeline (336)
Postmarket research (3243)
Preclinical (9551)
Radiopharmaceuticals (256)
Rare diseases (221)
Real estate (7125)
Regulatory (25184)
Research institute (2639)
Resumes & cover letters (578)
Southern California (1228)
Startups (4182)
United States (13542)
Vaccines (648)
Weight loss (216)
Date
Today (140)
Last 7 days (1024)
Last 30 days (3576)
Last 365 days (38167)
2024 (33884)
2023 (42565)
2022 (53926)
2021 (58725)
2020 (57668)
2019 (51305)
2018 (39085)
2017 (36831)
2016 (37740)
2015 (43730)
2014 (38416)
2013 (34389)
2012 (36287)
2011 (36406)
2010 (35834)
Location
Africa (1185)
Arizona (203)
Asia (47814)
Australia (8217)
California (3211)
Canada (1236)
China (246)
Colorado (141)
Connecticut (154)
Europe (107757)
Florida (432)
Georgia (118)
Illinois (390)
Indiana (207)
Kansas (102)
Maryland (601)
Massachusetts (2658)
Michigan (168)
Minnesota (284)
New Jersey (936)
New York (931)
North Carolina (808)
Northern California (1375)
Ohio (139)
Pennsylvania (813)
South America (1559)
Southern California (1228)
Texas (453)
Washington State (374)
801,442 Results for "zhejiang huahai pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Press Releases
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
November 8, 2024
·
7 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
BioMidwest
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.
June 21, 2024
·
3 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
NRx Pharmaceuticals, Inc. today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.
February 9, 2024
·
3 min read
Business
Meihua International Medical Technologies Co., Ltd. Reports 2023 Financial Year Results
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, reported its financial results for the fiscal year ended December 31, 2023.
April 24, 2024
·
14 min read
Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced the advance of the first $5 million milestone payment based on the Company’s partnership agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW).
February 12, 2024
·
3 min read
1 of 80,145
Next
